The European Medicines Agency’s human medicines committee (CHMP) endorsed Eli Lilly’s oral GLP-1 therapy orforglipron, clearing a regulatory milestone as the company tries to close the gap with Novo Nordisk’s oral GLP-1 franchise. The CHMP recommendation adds momentum to Lilly’s push to broaden the addressable market for GLP-1 drugs beyond injectables. The decision comes at a time when oral GLP-1 competition is intensifying and dosing convenience is becoming a differentiator in cardiometabolic care. Payers and clinicians will be watching for label details that could shape sequencing and combination strategies in real-world practice. For Lilly, the CHMP step is the latest in a broader portfolio strategy that increasingly targets metabolic-disease populations earlier and more broadly.